Sanofi’s Tzield Just Opened a Market That Didn’t Exist Last Week
Tzield's FDA approval for stage 3 type 1 diabetes creates a new disease-modifying therapy category for 2.1M U.S. patients...
cancer immunotherapy
The Molecular Logic Behind Roche’s Colon Cancer Priority Review That No One Is Explaining
Roche's FDA Priority Review for Tecentriq in dMMR/MSI-H stage III colon cancer has an October 9 decision date. Here's...
mRNA 2.0 Is Not a Science Story — It’s a $31 Billion Platform Bet That Most Pipelines Aren’t Priced For
Nature Reviews Drug Discovery maps mRNA's expansion into enzyme replacement and cancer immunotherapy—here's what it means for pipeline valuations...